Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Operating Expenses (2016 - 2020)

Historic Operating Expenses for Larimar Therapeutics (LRMR) over the last 8 years, with Q1 2020 value amounting to $3.6 million.

  • Larimar Therapeutics' Operating Expenses fell 7316.41% to $3.6 million in Q1 2020 from the same period last year, while for Dec 2020 it was $3.6 million, marking a year-over-year decrease of 9219.56%. This contributed to the annual value of $45.7 million for FY2019, which is 2530.68% down from last year.
  • Latest data reveals that Larimar Therapeutics reported Operating Expenses of $3.6 million as of Q1 2020, which was down 7316.41% from $7.3 million recorded in Q4 2019.
  • In the past 5 years, Larimar Therapeutics' Operating Expenses registered a high of $17.9 million during Q1 2016, and its lowest value of $3.6 million during Q1 2020.
  • Its 5-year average for Operating Expenses is $13.0 million, with a median of $13.4 million in 2017.
  • In the last 5 years, Larimar Therapeutics' Operating Expenses soared by 3487.16% in 2016 and then crashed by 7316.41% in 2020.
  • Larimar Therapeutics' Operating Expenses (Quarter) stood at $10.5 million in 2016, then grew by 27.52% to $13.4 million in 2017, then increased by 9.98% to $14.7 million in 2018, then plummeted by 50.44% to $7.3 million in 2019, then plummeted by 51.06% to $3.6 million in 2020.
  • Its Operating Expenses was $3.6 million in Q1 2020, compared to $7.3 million in Q4 2019 and $12.9 million in Q3 2019.